Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Employees

103

Sector

Biotechnology & Medical Research

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
16/07/25	1.290 $	+12.17%	4,905,071
15/07/25	1.150 $	-2.54%	3,296,079
14/07/25	1.180 $	+9.26%	3,054,129
11/07/25	1.080 $	-4.42%	3,260,067
10/07/25	1.130 $	+5.61%	5,308,688

Delayed Quote Nasdaq, July 16, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.150USD

Average target price

2.580USD

Spread / Average Target

+124.35%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 16/07/2025 BST			5-day change	1st Jan Change
1.290 ^USD	+12.17%		+20.56%	+74.68%

06-23	Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Clinical Study Data Showing A Reduction in Hypoglycemia Events When Added to Optimized Insulin	CI
06-11	Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple	RE

Capitalization	418M 358M 333M 310M 572M 35.84B 638M 4.04B 1.52B 16.81B 1.57B 1.53B 61.56B	P/E ratio 2025 *	-3.54x	P/E ratio 2026 *	-3.68x
Enterprise value	418M 358M 333M 310M 572M 35.84B 638M 4.04B 1.52B 16.81B 1.57B 1.53B 61.56B	EV / Sales 2025 *	30.2x	EV / Sales 2026 *	33.5x
Free-Float	98.44%	Yield 2025 *	-	Yield 2026 *	-

Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Clinical Study Data Showing A Reduction in Hypoglycemia Events When Added to Optimized Insulin	06-23	CI
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple	06-11	RE
Lexicon Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 13, 2025	06-11
Lexicon Pharmaceuticals, Inc. Announces Details of Its "Sotagliflozin" in Patients with Symptomatic Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy Study	05-19	CI
Lexicon Pharmaceuticals Q1 Operating Income USD -25.679 Million	05-13	RE
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-13	CI
Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline	04-01	MT
Novo Nordisk Gains Exclusive Rights to Lexicon's Non-incretin Obesity Drug Candidate	03-31	MT
Top Midday Gainers	03-28	MT
Novo Nordisk: licensing agreement with American Lexicon	03-28
Wall Street Set to Open Lower Friday as Inflation Rises More Than Expected	03-28	MT
Sector Update: Health Care Stocks Steady Premarket Friday	03-28	MT
Novo Nordisk in licensing deal with Lexicon - could pay up to $1 billion	03-28	FW

Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2	03-05	MT
HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating	11-22	MT
HC Wainwright Initiates Lexicon Pharmaceuticals With Buy Rating, $10 Price Target	17/06/24	MT
Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target	30/04/24	MT
Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $8 From $6, Keeps Buy Rating	31/05/23	MT

Lexicon Pharmaceuticals, Inc. Share Price

Equities

LXRX

US5288723027

Biotechnology & Medical Research

Valuation: Lexicon Pharmaceuticals, Inc.

Chart: Lexicon Pharmaceuticals, Inc.

Latest news: Lexicon Pharmaceuticals, Inc.

Last Transcript: Lexicon Pharmaceuticals, Inc.

Analysts' recommendations: Lexicon Pharmaceuticals, Inc.

Press Releases: Lexicon Pharmaceuticals, Inc.

News in other languages: Lexicon Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Lexicon Pharmaceuticals, Inc.

ETFs: Lexicon Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)	06-23	GL
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)	06-18	GL
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference	05-29	AQ
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology	05-19	GL
Lexicon: Q1 Earnings Snapshot	05-13	AQ

Novo Nordisk comprará licencia de medicamento de Lexicon en acuerdo por hasta 1.000 millones de dólares	03-28
Novo Nordisk : accord de licence avec l'américain Lexicon	03-28
MÄRKTE USA/Sinkende Renditen treiben Aktien weiter nach oben	10/10/23
MÄRKTE USA/Aktien starten gut behauptet - Anleihen fest	10/10/23
MÄRKTE USA/Aktien gut behauptet erwartet - Anleihen fest	10/10/23

1 day	+12.17%
1 week	+20.56%
Current month	+36.41%
1 month	+92.54%
3 months	+158.00%
6 months	+80.82%
Current year	+74.68%

1 week	1.05	1.33
1 month	0.65	1.33
Current year	0.28	1.33
1 year	0.28	2.45
3 years	0.28	3.79
5 years	0.28	9.65
10 years	0.28	19.62

Manager	Title	Age	Since
Michael Exton CEO	Chief Executive Officer	55	07/07/2024
Scott Coiante DFI	Director of Finance/CFO	58	01/01/2025
Craig Granowitz CTO	Chief Tech/Sci/R&D Officer	61	01/08/2021

Director	Title	Age	Since
Samuel Barker CHM	Chairman	82	31/12/2004
Ray Debbane CHM	Chairman	70	26/02/2012
Christopher Sobecki BRD	Director/Board Member	66	27/08/2007

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
LEXICON PHARMACEUTICALS, INC.	+12.17%	+20.56%	-42.15%	-54.26%	418M
ARGENX SE	+1.04%	+4.72%	+13.95%	+34.25%	34.18B
WUXI APPTEC CO., LTD.	-1.59%	+11.95%	+107.12%	-24.94%	31.87B
BIONTECH SE	+1.66%	+0.64%	+29.57%	-30.14%	27.25B
INSMED INCORPORATED	+1.67%	+8.42%	+34.12%	+362.38%	19.54B
SUMMIT THERAPEUTICS INC.	+16.05%	+14.27%	+209.98%	+2,446.85%	18.09B
WUXI BIOLOGICS (CAYMAN) INC.	-0.37%	+5.84%	+145.49%	-64.21%	14.15B
AKESO, INC.	+4.39%	+14.75%	+226.85%	+453.85%	13.8B
GENMAB A/S	+3.34%	+3.15%	-22.25%	-44.60%	13.02B
EXELIXIS, INC.	+1.70%	+1.68%	+96.88%	+107.74%	12.02B
Average	+4.03%	+7.44%	+79.96%	+318.69%	18.43B
Weighted average by Cap.	+2.61%	+5.62%	+82.50%	+308.93%

	2025 *	2026 *
Net sales	13.83M 11.85M 11.03M 10.28M 18.94M 1.19B 21.14M 134M 50.39M 557M 51.88M 50.81M 2.04B	12.47M 10.68M 9.94M 9.27M 17.08M 1.07B 19.06M 121M 45.42M 502M 46.77M 45.8M 1.84B
Net income	-120M -103M -95.4M -88.92M -164M -10.27B -183M -1.16B -436M -4.82B -449M -440M -17.64B	-130M -112M -104M -96.75M -178M -11.17B -199M -1.26B -474M -5.24B -488M -478M -19.19B
Net Debt	-	-